Back to Journals » ImmunoTargets and Therapy » Volume 8

Cytokine Release Syndrome: Current Perspectives

Authors Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA

Received 14 August 2019

Accepted for publication 7 October 2019

Published 29 October 2019 Volume 2019:8 Pages 43—52


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Michael Shurin

Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1

1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA

Correspondence: Mohamed A Kharfan-Dabaja
Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, 4500 San Pablo Road, Mangurian Bdg 3rd Floor, Jacksonville, FL 32224, USA
Tel +1 904 953-2000
Email KharfanDabaja.Mohamed@Mayo.Edu

Abstract: Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.

Keywords: cytokine release syndrome, chimeric antigen receptor T-cell therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]